Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment Supplementary Appendix

Aim: To elicit preferences for pharmacogenomic (PGx) testing in polypharmacy patients. Materials & methods: A face-to-face discrete choice experiment survey was designed and administered to adult polypharmacy patients recruited at a local retail pharmacy in Albuquerque (NM, USA). Results: A total of 128 eligible polypharmacy patients completed the discrete choice experiment survey and significantly preferred a PGx test with lower cost, better confidentiality and higher certainty of identifying best medication/dose and side effects and one that can be used to advocate for their treatment needs (all p patients. The study found most polypharmacy patients were willing to take a PGx test and their preferences were mostly influenced by test cost.研究目的：旨在探究多重用药患者对药物基因组学（pharmacogenomic, PGx）检测的偏好。材料与方法：设计并实施一项面对面离散选择实验（discrete choice experiment, DCE）调查，招募对象为在美国新墨西哥州阿尔伯克基市当地零售药房就诊的成年多重用药患者，并对其开展调查。研究结果：共计128名符合纳入标准的多重用药患者完成了本次离散选择实验调查，结果显示，受试者显著更青睐具备以下特征的药物基因组学检测：检测成本更低、保密性更佳、能够更精准地识别最优用药方案/剂量及不良反应，且可用于支持其治疗需求主张，上述各项差异均具有统计学意义。本研究发现，绝大多数多重用药患者愿意接受药物基因组学检测，且其检测偏好主要受检测成本因素影响。